Welcome
Support Centre
09 January 2009 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Double blind, randomised controlled cross over trial comparing the antihypertensive effects of amiloride and spironolactone in black hypertensives with and without the T594M mutation
ISRCTN ISRCTN21821912
ClinicalTrials.gov identifier
Public title Double blind, randomised controlled cross over trial comparing the antihypertensive effects of amiloride and spironolactone in black hypertensives with and without the T594M mutation
Scientific title
Acronym N/A
Serial number at source PG/2001084
Study hypothesis Not provided at time of registration
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Hypertension
Participants - inclusion criteria 1. Hypertensives of African origin
2. Subjects with the T594M polymorphism and controls with the wild-type sodium channel
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 01/01/2002
Anticipated end date 31/12/2002
Status of trial Completed
Patient information material
Target number of participants Not provided at time of registration
Interventions 1. Amiloride 5 mg bd for 2 weeks, increased to 10 mg bd for further 6 weeks. Then cross over to spironolactone as below, then to a combination of amiloride 5 mg bd plus spironolactone 25 mg bd
2. Spironolactone 25 mg bd for 2 weeks then increased to 50 mg bd for further 6 weeks. Then cross over to amiloride as above, then to a combination of amiloride 5 mg bd plus spironolactone 25 mg bd
Primary outcome measure(s) Not provided at time of registration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding British Heart Foundation (UK)
Trial website
Publications
Contact name Dr  PA  Swift
  Address Blood Pressure Unit
Department of Physiological Medicine
St George's Hospital Medical School
Cranmer Terrace
  City/town London
  Zip/Postcode SW17 0RE
  Country United Kingdom
  Tel +44 (0)20 8725 3176
  Fax +44 (0)20 8725 2959
  Email pswift@sghms.ac.uk
Sponsor British Heart Foundation (UK)
  Address 14 Fitzhardinge Street
  City/town London
  Zip/Postcode W1H 6DH
  Country United Kingdom
  Tel +44 (0)20 7935 0185
  Fax +44 (0)20 7486 5820
  Email research@bhf.org.uk
  Sponsor website: http://www.bhf.org.uk/
Date applied 08/03/2002
Last edited 18/12/2007
Date ISRCTN assigned 08/03/2002
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central